Received Sep 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 5J959 | — |
A patient received only the adjuvant portion of Arexvy.; A patient received only the adjuvant portion of Arexvy.; maladministration of the adjuvant portion of Arexvy alone to a 59 years old patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 59-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 5J959, expiry date 25-OCT-2025) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: A patient received only the adjuvant portion of Arexvy.), inappropriate dose of vaccine administered (Verbatim: A patient received only the adjuvant portion of Arexvy.) and inappropriate age at vaccine administration (Verbatim: maladministration of the adjuvant portion of Arexvy alone to a 59 years old patient). The outcome of the inappropriate preparation of medication, inappropriate dose of vaccine administered and inappropriate age at vaccine administration were not applicable. Additional Information: GSK Receipt Date: 03-SEP-2025 The nurse reported that there was maladministration of the adjuvant portion of Arexvy alone to a 59 years old male patient, which led to inappropriate preparation of medication, inappropriate dose of vaccine administered and inappropriate age at vaccine administration The reporter asked was there a time to revaccinate the patient